Controversies: Molecular vs. clinical systemic sclerosis classification

Journal of Scleroderma and Related Disorders

Volumn 1, Issue 3, 2016, Pages 277-285

  Johnson, Sindhu R ^a   Hinchcliff, Monique ^b   Asano, Yoshihide ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Clinical classification; Controversies; Molecular classification

Indexed keywords

AUTOANTIBODY;

CLINICAL TRIAL (TOPIC); DISEASE COURSE; DISEASE EXACERBATION; ELECTROCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROSIS; GENE EXPRESSION; HUMAN; HYPERTENSION; IMMUNODIFFUSION; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; INFLAMMATION; MODIFIED RODNAN SKIN SCORE; MORTALITY; PATIENT CARE; PROGNOSIS; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SKIN FIBROSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TELANGIECTASIA; VASCULAR DISEASE;

EID: 85018760622     PISSN: 23971983     EISSN: 23971991     Source Type: Journal    
DOI: 10.5301/jsrd.5000213     Document Type: Review

References (64)

1. Johnson SR. New ACR EULAR guidelines for systemic sclerosis classification. Curr Rheumatol Rep. 2015;17(5):32.
2. Masi AT, Medsger TA Jr, Rodnan GP, et al. Methods and preliminary results of the Scleroderma Criteria Cooperative Study of the American Rheumatology Association. Clin Rheum Dis. 1979;5(1):27-48.
3. Masi AT, Medsger TA Jr. Progress in the evolution of systemic sclerosis classification criteria and recommendation for additional comparative specificity studies. J Rheumatol. 2015; 42(1):8-10.
4. Rodnan GP, Jablonska S, Medsger TA. Classification and nomenclature of progressive systemic sclerosis. Clin Rheum Dis. 1979; 5(1):5-13.
5. Aggarwal R, Ringold S, Khanna D, et al. Distinctions between diagnostic and classification criteria? Arthritis Care Res (Hoboken). 2015;67(7):891-897.
6. Johnson SR, Goek ON, Singh-Grewal D, et al. Classification criteria in rheumatic diseases: a review of methodologic properties. Arthritis Rheum. 2007;57(7):1119-1133.
7. Masi AT. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980;23(5):581-590.
8. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Bull Rheum Dis. 1981;31(1):1-6.
9. Pope JE. Systemic sclerosis classification: a rose by any other name would smell as sweet? J Rheumatol. 2015;42(1):11-13.
10. Pope JE, Johnson SR. New Classification Criteria for Systemic Sclerosis (Scleroderma). Rheum Dis Clin North Am. 2015;41(3): 383-398.
11. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737-2747.
12. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747-1755.
13. Johnson SR, Fransen J, Khanna D, et al. Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res (Hoboken). 2012;64(3):358-367.
14. Coulter C, Baron M, Pope JE. A Delphi exercise and cluster analysis to aid in the development of potential classification criteria for systemic sclerosis using SSc experts and databases. Clin Exp Rheumatol. 2013;31(2)(Suppl 76):24-30.
15. Fransen J, Johnson SR, van den Hoogen F, et al. Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. Arthritis Care Res (Hoboken). 2012;64(3):351-357.
16. Johnson SR, Naden RP, Fransen J, et al. Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. J Clin Epidemiol. 2014;67(6): 706-714.
17. Alhajeri H, Hudson M, Fritzler M, et al. The 2013 ACR/EULAR Classification Criteria for Systemic Sclerosis Out-perform the 1980 Criteria. Data from the Canadian Scleroderma Research Group. Arthritis Care Res (Hoboken). 2015;67(4):582-7.
18. Hoffmann-Vold AM, Gunnarsson R, Garen T, et al. Performance of the 2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis (SSc) in large, well-defined cohorts of SSc and mixed connective tissue disease. J Rheumatol. 2015;42(1):60-63.
19. Johnson SR, Khanna D, Allanore Y, et al. Systemic sclerosis trial design moving forward. JSRD 2016;1(2):177-180.
20. Wigley FM. When is scleroderma really scleroderma? J Rheumatol. 2001;28(7):1471-1473.
21. Johnson SR, Soowamber M, Fransen J, et al. There is a need for new systemic sclerosis subset classification criteria: a content analytic approach. Arthritis Rheum. 2015;67(Suppl S10): 2257-2258.
22. Johnson SR, Laxer RM. Classification in systemic sclerosis. J Rheumatol. 2006;33(5):840-841.
23. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15(2):202-205.
24. Silman AJ. Scleroderma and survival. Ann Rheum Dis. 1991;50(4): 267-269.
25. Black CM, Welsh KI, Maddison PJ, et al. HLA antigens, autoantibodies and clinical subsets in scleroderma. Br J Rheumatol. 1984;23(4):267-271.
26. Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis - a report from the EULAR Scleroderma Trials And Research (EUSTAR) group data base. Ann Rheum Dis. 2007;66(6):754-763.
27. Giordano M, Valentini G, Migliaresi S, et al. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol. 1986;13(5):911-916.
28. Ferri C, Valentini G, Cozzi F, et al; Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc). Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore). 2002;81(2):139-153.
29. Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis. 1998;57(11):682-686.
30. Kane GC, Varga J, Conant EF, et al. Lung involvement in systemic sclerosis (scleroderma): relation to classification based on extent of skin involvement or autoantibody status. Respir Med. 1996;90(4):223-230.
31. Costenbader KH, Schur PH. We need better classification and terminology for “people at high-risk of or in the process of developing lupus“. Arthritis Care Res (Hoboken). 2015;67(5): 593-596.
32. Matucci-Cerinic M, Kahaleh B, Wigley FM. Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum. 2013;65(8):1953-1962.
33. Khanna D, Krishnan E, Dewitt EM, et al. The future of measuring patient-reported outcomes in rheumatology: Patient-Reported Outcomes Measurement Information System (PROMIS). Arthritis Care Res (Hoboken). 2011;63(S11)(Suppl 11):S486-S490.
34. Hinchcliff M, Just E, Podlusky S, et al. Text data extraction for a prospective, research-focused data mart: implementation and validation. BMC Med Inform Decis Mak. 2012;12(1):106.
35. Masi AT. Classification of systemic sclerosis (scleroderma): relationship of cutaneous subgroups in early disease to outcome and serologic reactivity. J Rheumatol. 1988;15(6): 894-898.
36. Maricq HR, Valter I. A working classification of scleroderma spectrum disorders: a proposal and the results of testing on a sample of patients. Clin Exp Rheumatol. 2004;22(3)(Suppl 33): S5-S13.
37. Avouac J, Fransen J, Walker UA, et al; EUSTAR Group. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis. 2011;70(3): 476-481.
38. Bellando-Randone S, Matucci-Cerinic M. From Raynaud’s Phenomenon to very early diagnosis of systemic sclerosis - the VEDOSS approach. Curr Rheumatol Rev. 2013;9(4):245-248.
39. Minier T, Guiducci S, Bellando-Randone S, et al; EUSTAR coworkers; EUSTAR co-workers. Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis. 2014;73(12): 2087-2093.
40. Varga J, Hinchcliff M. Connective tissue diseases: systemic sclerosis: beyond limited and diffuse subsets? Nat Rev Rheumatol. 2014;10(4):200-202.
41. Becker MO, Riemekasten G. Risk factors for severity and manifestations in systemic sclerosis and prediction of disease course. Expert Rev Clin Immunol. 2016;12(2):115-135.
42. Czirják L, Foeldvari I, Müller-Ladner U. Skin involvement in systemic sclerosis. Rheumatology (Oxford). 2008;47(Suppl 5): v44-v45.
43. Shand L, Lunt M, Nihtyanova S, et al. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum. 2007;56(7):2422-2431.
44. Okutucu S, Karakulak UN, Aksoy H, et al. Prolonged Tp-e interval and Tp-e/QT correlates well with modified Rodnan skin severity score in patients with systemic sclerosis. Cardiol J. 2016;23(3):242-249.
45. Kimmel JN, Carlson DA, Hinchcliff M, et al. The association between systemic sclerosis disease manifestations and esophageal high-resolution manometry parameters. Neurogastroenterol Motil. 2016;28(8):1157-1165.
46. Maurer B, Graf N, Michel BA, et al; EUSTAR co-authors. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann Rheum Dis. 2015;74(6):1124-1131.
47. Domsic RT, Rodriguez-Reyna T, Lucas M, et al. Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis. 2011;70(1):104-109.
48. Pope JE, Baron M, Bellamy N, et al. Variability of skin scores and clinical measurements in scleroderma. J Rheumatol. 1995;22(7): 1271-1276.
49. Clements PJ, Lachenbruch PA, Seibold JR, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol. 1993;20(11): 1892-1896.
50. Howe S, Eaker EY, Sallustio JE, et al. Antimyenteric neuronal antibodies in scleroderma. J Clin Invest. 1994;94(2):761-770.
51. Eaker EY, Kuldau JG, Verne GN, et al. Myenteric neuronal antibodies in scleroderma: passive transfer evokes alterations in intestinal myoelectric activity in a rat model. J Lab Clin Med. 1999;133(6):551-556.
52. Schachna L, Wigley FM, Morris S, et al. Recognition of Granzyme B-generated autoantigen fragments in scleroderma patients with ischemic digital loss. Arthritis Rheum. 2002;46(7): 1873-1884.
53. Salazar GA, Assassi S, Wigley F, et al. Antinuclear antibody-negative systemic sclerosis. Semin Arthritis Rheum. 2014.
54. Assassi S, Wu M, Tan FK, et al. Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis. Arthritis Rheum. 2013;65(11):2917-2927.
55. Farina G, Lafyatis D, Lemaire R, et al. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2010;62(2):580-588.
56. Rice LM, Stifano G, Ziemek J, et al. Local skin gene expression reflects both local and systemic skin disease in patients with systemic sclerosis. Rheumatology (Oxford). 2016;55(2):377-379.
57. Assassi S, Mayes MD, Arnett FC, et al. Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum. 2010;62(2):589-598.
58. Longo DL, Drazen JM. Data Sharing. N Engl J Med. 2016; 374(3): 276-277.
59. Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387(10038): 2630-2640.
60. Rice LM, Padilla CM, McLaughlin SR, et al. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest. 2015;125(7):2795-2807.
61. Rice LM, Ziemek J, Stratton EA, et al. A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum (Munch). 2015;67(11): 3004-3015.
62. Jordan S, Distler JH, Maurer B, et al; EUSTAR Rituximab study group. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74(6):1188-1194.
63. Becker MO, Bruckner C, Scherer HU, et al. The monoclonal anti-CD25 antibody basiliximab for the treatment of progressive systemic sclerosis: an open-label study. Ann Rheum Dis. 2011;70(7):1340-1341.
64. Elhai M, Meunier M, Matucci-Cerinic M, et al; EUSTAR (EULAR Scleroderma Trials and Research group). Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis. 2013;72(7):1217-1220.